Opens in a new tab
Home > All posts > News > Safety Update on Gene Therapy for Spinal Muscular Atrophy (SMA)

Safety Update on Gene Therapy for Spinal Muscular Atrophy (SMA)

ERN EURO-NMD wishes to inform patients, families and healthcare professionals about recent safety concerns regarding AAV-based gene therapies for SMA, following reports of malignancies in patients treated with Zolgensma.

It is important to emphasise that only a very small number of cases have been reported among more than 6,000 patients treated worldwide. Nevertheless, the long-term risk remains uncertain.

These findings highlight the importance of ongoing safety monitoring and continued regulatory surveillance. Patients and families are encouraged to discuss any concerns with their treating specialists.

Read SMA Europe website information here

 

Link to FDA advice